Cargando…
Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
Autor principal: | Lott, Felipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Urologia
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712714/ https://www.ncbi.nlm.nih.gov/pubmed/33047929 http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.01.08 |
Ejemplares similares
-
Editorial Comment: Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension
por: Lott, Felipe
Publicado: (2020) -
Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
por: Lott, Felipe
Publicado: (2020) -
Editorial Comment: Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease
por: Lott, Felipe
Publicado: (2020) -
Editorial Comment: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
por: Hugosson, J, et al.
Publicado: (2020) -
Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study
por: Lott, Felipe
Publicado: (2020)